Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GDRX
stocks logo

GDRX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
192.82M
-2.9%
0.035
+250%
193.75M
-4.54%
0.031
+56.65%
200.59M
-1.22%
0.028
-8.33%
Estimates Revision
The market is revising Downward the revenue expectations for GoodRx Holdings, Inc. (GDRX) for FY2025, with the revenue forecasts being adjusted by -0.52% over the past three months. During the same period, the stock price has changed by -31.25%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.52%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-19.35%
In Past 3 Month
Stock Price
Go Down
down Image
-31.25%
In Past 3 Month
Wall Street analysts forecast GDRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GDRX is 4.97 USD with a low forecast of 3.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast GDRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GDRX is 4.97 USD with a low forecast of 3.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
4 Hold
1 Sell
Moderate Buy
Current: 2.750
sliders
Low
3.00
Averages
4.97
High
7.00
Current: 2.750
sliders
Low
3.00
Averages
4.97
High
7.00
BofA
BofA
Underperform
maintain
$3
2025-11-17
Reason
BofA
BofA
Price Target
$3
2025-11-17
maintain
Underperform
Reason
BofA lowered the firm's price target on GoodRx to $3 from $3.40 and keeps an Underperform rating on the shares after the company announced two initiatives for its weight loss offering. BofA sees the announcement positively as the collaboration builds on GoodRx's existing partnership with Novo Nordisk and further expands the subscription offering, the firm told investors. BofA acknowledged the progress that GoodRx is making to expand partnerships but maintained its Underperform rating given broader headwinds from pharmacy closures and reimbursement changes in the pharmacy ecosystem.
JPMorgan
Lisa Gill
Overweight
downgrade
$6 -> $5
2025-11-11
Reason
JPMorgan
Lisa Gill
Price Target
$6 -> $5
2025-11-11
downgrade
Overweight
Reason
JPMorgan analyst Lisa Gill lowered the firm's price target on GoodRx to $5 from $6 and keeps an Overweight rating on the shares. The firm updated the company's model.
TD Cowen
Buy
downgrade
$7 -> $6
2025-11-10
Reason
TD Cowen
Price Target
$7 -> $6
2025-11-10
downgrade
Buy
Reason
TD Cowen lowered the firm's price target on GoodRx to $6 from $7 and keeps a Buy rating on the shares. The firm said some new offerings show promise and company's role in Cigna's new PBM model is potential positive, but material impact unlikely until at least 2027. That said, valuation overly discounts the weaker near-term outlook.
Mizuho
Neutral
downgrade
$5 -> $4
2025-11-06
Reason
Mizuho
Price Target
$5 -> $4
2025-11-06
downgrade
Neutral
Reason
Mizuho lowered the firm's price target on GoodRx to $4 from $5 and keeps a Neutral rating on the shares.
UBS
Kevin Caliendo
Neutral
downgrade
$4
2025-11-06
Reason
UBS
Kevin Caliendo
Price Target
$4
2025-11-06
downgrade
Neutral
Reason
UBS analyst Kevin Caliendo lowered the firm's price target on GoodRx to $4 from $4.25 and keeps a Neutral rating on the shares.
Citi
Buy
maintain
$5.75
2025-10-01
Reason
Citi
Price Target
$5.75
2025-10-01
maintain
Buy
Reason
Citi reiterated a Buy rating and $5.75 price target on GoodRx, noting the stock jump following CEO Wendy Barnes' comments on Fox Business around potentially partnering with TrumpRx. Initially, the firm thought TrumpRx could be a potential competitor to GoodRx depending on patient awareness. A partnership would be "welcome news," and is in line with the firm's recent conversation with CFO Chris McGinnis, where he highlighted how the company is well-positioned to benefit from the shift to direct-to-consumer drug channel, the analyst tells investors in a research note. While the details are sparse, the firms aid it could imagine a TrumpRx website/app that integrates GoodRx to provide access to its pricing.
See All Ratings

Valuation Metrics

The current forward P/E ratio for GoodRx Holdings Inc (GDRX.O) is 19.12, compared to its 5-year average forward P/E of 112.89. For a more detailed relative valuation and DCF analysis to assess GoodRx Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
112.89
Current PE
19.12
Overvalued PE
761.51
Undervalued PE
-535.72

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
22.47
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
44.07
Undervalued EV/EBITDA
0.88

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
6.82
Current PS
0.00
Overvalued PS
13.77
Undervalued PS
-0.14
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 1160% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

GDRX News & Events

Events Timeline

(ET)
2025-11-17
08:59:00
GoodRx Launches Weight Loss Telemedicine Subscription and Partners with Novo Nordisk
select
2025-11-17
08:23:28
Novo introduces a $199 monthly self-pay option for Wegovy and Ozempic.
select
2025-11-06 (ET)
2025-11-06
14:42:51
GoodRx Declines Partnership with TrumpRx, According to CBS News
select
link
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
01:01 AMMarketWatch
Wegovy Prices Are Decreasing, Yet They Remain 'Significantly Varied' and Confusing
  • Cost Variability: The price of Novo Nordisk’s weight-loss drug Wegovy varies significantly based on individual medical coverage and federal policies.
  • Influencing Factors: Corporate pricing strategies and the necessity for thorough research also play crucial roles in determining the drug's cost.
[object Object]
Preview
3.0
11-29NASDAQ.COM
HIMS vs. GDRX: Which Health Stock Presents More Potential for Growth?

  • Virtual Healthcare Platforms: Hims & Hers Health, Inc. and GoodRx Holdings, Inc. are leading the digital healthcare shift, with HIMS focusing on subscription telehealth services and GDRX emphasizing prescription price transparency and affordability programs.

  • Stock Performance: Over the past year, HIMS has outperformed GDRX, with respective stock movements of +19.1% and -41.6%. HIMS is currently trading at a higher price-to-sales ratio compared to GDRX, which is considered undervalued in the medical sector.

  • Expansion Strategies: HIMS is diversifying its offerings into recurring-care specialties and enhancing its platform with AI-driven solutions, while GDRX is scaling its pharma-manufacturer solutions and introducing subscription-driven care to deepen consumer engagement.

  • Investment Outlook: HIMS is viewed as a more stable investment opportunity due to its improving profitability and subscriber engagement, whereas GDRX, while diversifying its revenue streams, faces more volatility linked to prescription transaction volumes.

[object Object]
Preview
5.0
11-18Benzinga
Novo Nordisk Focuses on Cost-Effectiveness in Response to Increasing Competition

  • Pricing Announcement: Novo Nordisk has introduced a limited-time offer for new self-pay patients, allowing them to access Wegovy and Ozempic at $199 per month for the first two months, after which the price will drop to $349 per month.

  • Access and Distribution: Patients can access these offers through various platforms, including wegovy.com, ozempic.com, and participating pharmacies, with additional savings programs available for those with commercial insurance.

  • Wegovy Pill Launch: The company is preparing for the launch of a Wegovy pill, aiming to avoid supply shortages experienced with the injectable version, and expects U.S. regulatory approval by the end of the year.

  • Market Position: Despite recent slowing growth in its obesity franchise due to supply issues, Novo Nordisk is taking steps to maintain its competitive edge against rivals like Eli Lilly.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is GoodRx Holdings Inc (GDRX) stock price today?

The current price of GDRX is 2.75 USD — it has increased 0.36 % in the last trading day.

arrow icon

What is GoodRx Holdings Inc (GDRX)'s business?

GoodRx Holdings, Inc. is a platform for medication savings in the United States, used by consumers and healthcare professionals. The Company connects consumers, healthcare professionals, payers, pharmacy benefit managers (PBMs), pharma manufacturers, and retail pharmacies to make saving on medications easier. The Company's offerings include prescription marketplace and pharma manufacturer solutions. Its prescription marketplace consists of its prescription transactions offering and its supplemental subscription and telehealth offerings. Through its GoodRx Care platform, the Company offers consumers access to telehealth visits on a cash-pay basis outside of insurance. The Company partners with pharma manufacturers to advertise and integrate their affordability solutions into its platform. These solutions, provided by pharma manufacturers, include co-pay cards, patient assistance programs, care portals, and other savings options to ensure consumers can access their medications.

arrow icon

What is the price predicton of GDRX Stock?

Wall Street analysts forecast GDRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GDRX is 4.97 USD with a low forecast of 3.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is GoodRx Holdings Inc (GDRX)'s revenue for the last quarter?

GoodRx Holdings Inc revenue for the last quarter amounts to 196.03M USD, increased 0.40 % YoY.

arrow icon

What is GoodRx Holdings Inc (GDRX)'s earnings per share (EPS) for the last quarter?

GoodRx Holdings Inc. EPS for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for GoodRx Holdings Inc (GDRX)'s fundamentals?

The market is revising Downward the revenue expectations for GoodRx Holdings, Inc. (GDRX) for FY2025, with the revenue forecasts being adjusted by -0.52% over the past three months. During the same period, the stock price has changed by -31.25%.
arrow icon

How many employees does GoodRx Holdings Inc (GDRX). have?

GoodRx Holdings Inc (GDRX) has 738 emplpoyees as of December 05 2025.

arrow icon

What is GoodRx Holdings Inc (GDRX) market cap?

Today GDRX has the market capitalization of 931.74M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free